- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06310564
Low and Intermediate Risk oliGometastatic coloREctal cancEr patieNts Treated With Stereotactic ABlative Radiotherapy (GREENLaIT-SABR)
A Prospective, Randomized Clinical Trial of Low and Intermediate Risk oliGometastatic coloREctal cancEr patieNts Treated With Stereotactic ABlative Radiotherapy: GREEN LaIT-SABR Study
This is an experimental study without drug or device, randomized, open-label, non-profit, sponsored by the IRCCS Sacro Cuore Don Calabria Hospital in Negrar, which will take place at the Department of Advanced Oncological Radiotherapy and 18 other Italian centers.
The reason for this research study is to evaluate whether stereotactic radiotherapy treatment (SABR), in addition to the systemic chemotherapy treatment foreseen by clinical practice for low-intermediate risk oligometastatic colorectal cancer, is able to:
- delay possible local recurrence and/or distant polymetastatic progression
- improve disease-free survival
- reduce side effects in the short and long term
thus inducing an improvement in the quality of life of patients suffering from this type of pathology.
Therefore, as part of this randomized study, before starting first or second line systemic therapy for his tumor, the patient will be randomized to one of the following treatment arms:
- Experimental arm: ablative stereotactic radiotherapy on all sites of oligometastatic disease (from 1 to 3 sites, performed at most within the second cycle of systemic therapy)
- Control arm: no ablative stereotactic radiotherapy to sites of oligometastatic disease
The procedure that is intended to be tested in the experimental arm is a stereotactic radiotherapy treatment on oligometastases (up to a maximum of 3 sites), with ablative dosage (effective biological dose >100 Gy), performed before the start of systemic therapy of I or II line (at most within the second cycle of the same).
It is hoped that the addition of this type of radiotherapy will increase the potential clinical benefit of the treatment in the context of colorectal cancer.
Study Overview
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Verona
-
Negrar, Verona, Italy, 37024
- IRCCS Sacro Cuore Don Calabria di Negrar
-
Contact:
- Luca Nicosia, Doctor
- Phone Number: +39(0)456014800
- Email: luca.nicosia@sacrocuore.it
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age ≥18 years
- Histologically confirmed CRC
- Low and intermediate risk oligometastatic colorectal cancer with 1 to 3 metastases, candidate to I or II line systemic treatment (Low risk: 1 to 3 metastases and cumulative tumor volume smaller than 10 cm3; Intermediate risk: 1 to 3 metastases and cumulative tumor volume bigger than 10 cm3).
- Controlled primary tumor regardless of primary surgery or primary systemic treatment
- ECOG/WHO 0-2
- Life expectancy > 6 months
- Lesions ≤ 5 cm
- Adequate organ function for the planned treatment according to local guidelines
- For patients with liver metastases: no cirrhosis or hepatitis, and evidence of adequate hepatic function (Total bilirubin level < 1.5 x institutional ULN; ALT and AST levels < 3.0 x institutional ULN, GGT and alkaline phosphatase levels < 3.0 x institutional ULN; INR and APTT levels < 1.5 x institutional ULN, Albumin > 2.5 mg/dL)
- For patients with liver metastases: unresectable liver metastases (assessed by a surgeon, preferably hepatobiliary) or refusal of liver surgery before study screening.
- If childbearing potential, willing to use an effective form of contraception throughout the duration of the study
- Signed informed consent and willingness to follow the trial procedures
Exclusion Criteria:
- Age < 18 years
- Brain metastases
- Having more than 3 metastases
- Malignant pleural effusion or ascites
- Unable to undergo imaging by either CT scan or MRI
- Evidence of any other medical conditions (such as psychiatric illness, infectious diseases, neurological conditions, physical examination or laboratory findings) that may interfere with the planned treatment or affect patient compliance.
- Pregnancy or breast-feeding
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: stereotactic ablative radiotherapy (SABR)
SABR to all the active sites of disease (1-3 oligometastases).
3D-CRT, IMRT and VMAT techniques are allowed, but IMRT and VMAT are strongly suggested.
|
A biological effective dose (BED) ≥125 Gy10 should be administered when constraints to the organs at risk (OARs) are respected [10]; if not possible, a BED schedule no lower than 100 Gy10 should be administered. In compliance with these instructions, treatment schedules, total dose and fractionation will be prescribed according to the clinical practice of each participating Center. The constraints for the organs at risk will be respected according to the available data. In any case, biological effective dose (BED) ≥125 Gy10 should be administered when constraints to the organs at risk (OARs) are respected; if not possible, a BED schedule no lower than 100 Gy10 should be administered. SABR will be administered before systemic treatment start, or before starting the second systemic treatment cycle at the latest. |
No Intervention: no SABR
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-free survival (PFS).
Time Frame: 7 years
|
PFS is defined as the time between randomization to the radiological evidence of disease progression. For patients with a PFS event, PFS will be calculated as the time interval from the date of randomization to the date of first objective evidence of disease progression or death from any cause, whichever occurs first. For patients without a PFS event, PFS will be censored at the date of the last radiographic assessment prior to the date of study end. |
7 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to the polymetastatic conversion (tPMC)
Time Frame: 7 years
|
tPMC will be defined as the time between randomization to the date of radiological occurrence of >5 new metastases.
For patients without a tPMC event, time to tPMC will be censored at the date of the last radiographic assessment prior to the study end date.
|
7 years
|
Local control (LC): the time between randomization to the date of radiological development of local progression after SABR.
Time Frame: 7 years
|
For patients without LC, time to LC will be censored at the date of the last radiographic assessment prior to the study end date.
|
7 years
|
Overall survival (OS)
Time Frame: 7 years
|
OS will be defined as the time between randomization to the date of death or last follow-up.
For patients who are alive at the time of the study end date, OS time will be censored on the last date the patient is known to be alive or the study end date, whichever occurs first.
|
7 years
|
Time to start of the next systemic treatment line (NEST)
Time Frame: 7 years
|
For patients without a NEST, time to NEST will be censored at the date of the last patient visit before the study end date.
|
7 years
|
Number of adverse events as assessed by CTCAE v4.0
Time Frame: 60 months
|
Number of adverse events as assessed by CTCAE v4.0
|
60 months
|
Number of acute side-effects
Time Frame: from enrollment until 6 months after the last dose of SABR
|
Acute side-effects
|
from enrollment until 6 months after the last dose of SABR
|
Number of Late side-effects
Time Frame: from the 6 months after the last dose of SABR until up to 3 years after inclusion in the trial
|
Late side-effects
|
from the 6 months after the last dose of SABR until up to 3 years after inclusion in the trial
|
questionnaire QLQ-C30
Time Frame: 60 months
|
Quality of life (QoL): QoL will be evaluate with the questionnaire QLQ-C30
|
60 months
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2023-18
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Colorectal Cancer
-
University of California, San FranciscoCompletedStage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC... and other conditionsUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)TerminatedRectal Cancer | Colon Cancer | Cancer Survivor | Colorectal Adenocarcinoma | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC v8 | Stage I Colorectal Cancer AJCC v8 | Stage II Colorectal Cancer AJCC v8 | Stage... and other conditionsUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedStage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingStage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC... and other conditionsUnited States
-
M.D. Anderson Cancer CenterRecruitingColorectal Adenocarcinoma | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC v8 | Stage... and other conditionsUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedCancer Survivor | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC v8 | Stage I Colorectal Cancer AJCC v8 | Stage II Colorectal Cancer AJCC v8 | Stage IIA Colorectal Cancer AJCC v8 | Stage IIB Colorectal... and other conditionsUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...United States Department of DefenseActive, not recruitingColorectal Adenoma | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC v8 | Stage 0 Colorectal Cancer AJCC v8 | Stage I Colorectal Cancer AJCC v8 | Stage II Colorectal Cancer AJCC v8 | Stage IIA Colorectal... and other conditionsUnited States
-
City of Hope Medical CenterRecruitingColorectal Neoplasms | Colorectal Cancer | Colorectal Adenocarcinoma | Colorectal Cancer Stage II | Colorectal Cancer Stage III | Colorectal Cancer Stage IV | Colorectal Neoplasms Malignant | Colorectal Cancer Stage IUnited States, Japan, Italy, Spain
-
University of Roma La SapienzaCompletedColorectal Cancer Stage II | Colorectal Cancer Stage III | Colorectal Cancer Stage IV | Colorectal Cancer Stage 0 | Colorectal Cancer Stage IItaly
-
University of Southern CaliforniaNational Cancer Institute (NCI); AmgenTerminatedStage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Colorectal Adenocarcinoma | RAS Wild Type | Stage III Colorectal Cancer AJCC v7 | Stage IIIA Colorectal Cancer AJCC v7 | Stage IIIB Colorectal Cancer AJCC v7 | Stage IIIC Colorectal Cancer...United States
Clinical Trials on SABR
-
Stanford UniversityRecruitingLung CancerUnited States
-
Trans Tasman Radiation Oncology GroupAustralasian Lung Cancer Trials GroupCompletedCancer | Metastases to the LungAustralia
-
M.D. Anderson Cancer CenterVarian Medical SystemsCompleted
-
Vastra Gotaland RegionKarolinska University Hospital; Oslo University Hospital; University Hospital... and other collaboratorsRecruitingBreast Cancer Stage IV | Oligometastatic DiseaseSweden
-
Sunnybrook Health Sciences CentreActive, not recruiting
-
Institute of Cancer Research, United KingdomProstate Cancer UKRecruitingProstate CancerUnited Kingdom
-
King Saud UniversityRecruiting
-
Toronto Sunnybrook Regional Cancer CentreRecruiting